77 related articles for article (PubMed ID: 22450127)
1. Pyrazolopyrimidines as dual Akt/p70S6K inhibitors.
Rice KD; Kim MH; Bussenius J; Anand NK; Blazey CM; Bowles OJ; Canne-Bannen L; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Klein RR; Laird AD; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W
Bioorg Med Chem Lett; 2012 Apr; 22(8):2693-7. PubMed ID: 22450127
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
Bussenius J; Anand NK; Blazey CM; Bowles OJ; Bannen LC; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Kim MH; Klein RR; Laird D; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W; Rice KD
Bioorg Med Chem Lett; 2012 Mar; 22(6):2283-6. PubMed ID: 22342124
[TBL] [Abstract][Full Text] [Related]
3. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
Zhu GD; Gong J; Gandhi VB; Woods K; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Stoll VS; Mamo M; Li Q; Rosenberg SH; Giranda VL
Bioorg Med Chem; 2007 Mar; 15(6):2441-52. PubMed ID: 17258463
[TBL] [Abstract][Full Text] [Related]
5. Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
Kendall JD; O'Connor PD; Marshall AJ; Frédérick R; Marshall ES; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):69-85. PubMed ID: 22177405
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
[TBL] [Abstract][Full Text] [Related]
7. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
[TBL] [Abstract][Full Text] [Related]
9. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies.
Gilbert AM; Nowak P; Brooijmans N; Bursavich MG; Dehnhardt C; Santos ED; Feldberg LR; Hollander I; Kim S; Lombardi S; Park K; Venkatesan AM; Mallon R
Bioorg Med Chem Lett; 2010 Jan; 20(2):636-9. PubMed ID: 19969455
[TBL] [Abstract][Full Text] [Related]
10. Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
Kendall JD; Giddens AC; Tsang KY; Frédérick R; Marshall ES; Singh R; Lill CL; Lee WJ; Kolekar S; Chao M; Malik A; Yu S; Chaussade C; Buchanan C; Rewcastle GW; Baguley BC; Flanagan JU; Jamieson SM; Denny WA; Shepherd PR
Bioorg Med Chem; 2012 Jan; 20(1):58-68. PubMed ID: 22177407
[TBL] [Abstract][Full Text] [Related]
11. Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.
Paruch K; Dwyer MP; Alvarez C; Brown C; Chan TY; Doll RJ; Keertikar K; Knutson C; McKittrick B; Rivera J; Rossman R; Tucker G; Fischmann TO; Hruza A; Madison V; Nomeir AA; Wang Y; Lees E; Parry D; Sgambellone N; Seghezzi W; Schultz L; Shanahan F; Wiswell D; Xu X; Zhou Q; James RA; Paradkar VM; Park H; Rokosz LR; Stauffer TM; Guzi TJ
Bioorg Med Chem Lett; 2007 Nov; 17(22):6220-3. PubMed ID: 17904841
[TBL] [Abstract][Full Text] [Related]
12. Role of the phosphoinositide 3-kinase-Akt-mammalian target of the rapamycin signaling pathway in long-term potentiation and trace fear conditioning memory in rat medial prefrontal cortex.
Sui L; Wang J; Li BM
Learn Mem; 2008 Oct; 15(10):762-76. PubMed ID: 18832563
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors.
Xiao Y; Huck BR; Lan R; DeSelm L; Chen X; Qiu H; Neagu C; Johnson T; Mochalkin I; Gardberg A; Jiang X; Tian H; Dutt V; Santos D; Head J; Jackson J; Syed S; Lin J; Wilker E; Ma J; Clark A; Machl A; Bankston D; Jones CCV; Goutopoulos A; Sherer B
Bioorg Med Chem Lett; 2021 Oct; 50():128352. PubMed ID: 34481987
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
16. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
17. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
Sekulić A; Hudson CC; Homme JL; Yin P; Otterness DM; Karnitz LM; Abraham RT
Cancer Res; 2000 Jul; 60(13):3504-13. PubMed ID: 10910062
[TBL] [Abstract][Full Text] [Related]
18. Lesion-targeted thrombopoietin potentiates vasculogenesis by enhancing motility and enlivenment of transplanted endothelial progenitor cells via activation of Akt/mTOR/p70S6kinase signaling pathway.
Eguchi M; Masuda H; Kwon S; Shirakura K; Shizuno T; Ito R; Kobori M; Asahara T
J Mol Cell Cardiol; 2008 Nov; 45(5):661-9. PubMed ID: 18773906
[TBL] [Abstract][Full Text] [Related]
19. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
20. Non-oxime pyrazole based inhibitors of B-Raf kinase.
Newhouse BJ; Hansen JD; Grina J; Welch M; Topalov G; Littman N; Callejo M; Martinson M; Galbraith S; Laird ER; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
Bioorg Med Chem Lett; 2011 Jun; 21(11):3488-92. PubMed ID: 21536432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
